For the quarter ending 2025-09-30, ENSC has $3,179,464 in assets. $2,304,750 in debts. $1,673,218 in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 1,673,218 | 2,211,575 | ||
| Unbilled receivable | 4,411 | 1,204,979 | ||
| Prepaid expenses and other current assets | 1,250,641 | 1,865,041 | ||
| Total current assets | 2,928,270 | 5,281,595 | ||
| Property and equipment, net | 123,643 | - | ||
| Other assets | 127,551 | 292,860 | ||
| Total assets | 3,179,464 | 5,574,455 | ||
| Accounts payable | 463,458 | 1,042,832 | ||
| Accrued expenses and other liabilities | 1,453,555 | 1,045,657 | ||
| Notes payable and accrued interest | 387,702 | 424,521 | ||
| Total current liabilities | 2,304,715 | 2,513,010 | ||
| Other long-term liabilities | 35 | 1,033 | ||
| Total long-term liabilities | 35 | 1,033 | ||
| Total liabilities | 2,304,750 | 2,514,043 | ||
| Common stock, 0.0001 par value, 250,000,000 shares authorized at september 30, 2025 and december 31, 2024 3,181,080 and 1,355,779 shares issued atseptember 30, 2025 and december 31, 2024, respectively 3,181,074 and 1,355,773shares outstanding at september 30, 2025 and december 31, 2024, respectively | 320 | 241 | ||
| Additional paid-in capital | 138,155,394 | 136,612,043 | ||
| Accumulated deficit | -136,952,351 | -133,223,223 | ||
| Total ensysce biosciences, inc. stockholders equity | 1,203,363 | 3,389,061 | ||
| Noncontrolling interests in stockholders equity | -328,649 | -328,649 | ||
| Total stockholders equity | 874,714 | 3,060,412 | ||
| Total liabilities and stockholders equity | 3,179,464 | 5,574,455 | ||
Ensysce Biosciences, Inc. (ENSC)
Ensysce Biosciences, Inc. (ENSC)